InflaRx Plans Two Phase 2 Izicopan Trials in ANCA-Associated Vasculitis in 2027

Bitget2026/11/03 12:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

InflaRx plans two Phase 2 izicopan trials in ANCA-associated vasculitis starting in 2027, with first results expected in 2028.
A placebo-controlled trial will assess kidney benefits; an open-label study will test whether izicopan can replace corticosteroids safely.
An independent commercial assessment estimates izicopan's peak sales potential at $1.5 billion to $2 billion in ANCA-associated vasculitis.
Additional kidney-disease studies target initial atypical hemolytic uremic syndrome data in late 2027, followed by IgA nephropathy data in 2028.
Cash, cash equivalents and marketable securities totaled €153.3 million on September 30, 2026, with funding expected to support operations through 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611030700PRIMZONEFULLFEED9868976) on November 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

InflaRx Plans Two Phase 2 Izicopan Trials in ANCA-Associated Vasculitis in 2027

You may also like

Crypto prices